ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1114

Longitudinally Assessed Structural Abnormalities on MRI and Relative Contributions to Risk of Incident Radiographic Knee Osteoarthritis over 10 Years of Follow-up

C. Kent Kwoh1, Ali Guermazi2, Erin Ashbeck3, Chengcheng Hu3, Edward Bedrick3, Leena Sharma4, Charles Eaton5, Marc Hochberg6, Rebecca Jackson7, Timothy McAlindon8, Michael Nevitt9, Jane Cauley10 and Frank Roemer11, 1University of Arizona of Arizona Arthritis Center and Division of Rheumatology, College of Medicine, University of Arizona, Tucson, AZ, 2Boston University School of Medicine, Boston, MA, 3University of Arizona, Tucson, AZ, 4Northwestern University Feinberg School of Medicine, Chicago, IL, 5Department of Family Medicine and Epidemiology, Warren Alpert Medical School of Brown University,Department of Epidemiology, School of Public Health of Brown University, Providence, RI, 6University of Maryland School of Medicine, Baltimore, MD, 7Ohio State University, Columbus, OH, 8Tufts Medical Center, Boston, MA, 9University of California, San Francisco, San Francisco, CA, 10University of Pittsburgh, Pittsburgh, PA, 11Boston University School of Medicine, Boston, MA, and Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany, Erlangen, Germany

Meeting: ACR Convergence 2020

Keywords: Biomarkers, Epidemiology, Magnetic resonance imaging (MRI), Osteoarthritis, X-ray

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 8, 2020

Title: Osteoarthritis – Clinical Poster I

Session Type: Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: MRI has identified joint tissues affected during knee OA development, though the relative importance of structures in the pathogenic process is unknown. Our objective was to estimate relative contributions of structural abnormalities to risk of incident radiographic knee OA (iRKOA), with assessment of longitudinal MRI during 10 year follow-up.

Methods: We conducted a case-cohort study with 10 year follow-up. The parent cohort included 2,987 Osteoarthritis Initiative participants with at least one knee at risk of developing iRKOA (i.e., Kellgren-Lawrence [KL] 0 or 1 at baseline). Within the parent cohort, participants who developed iRKOA (cases, n=844) and a random sample of the parent cohort (subcohort, n=868) were identified for MRI readings, a total of 1,455 participants (Figure 1). If a participant had two knees at risk, we selected the first knee to develop iRKOA or otherwise selected a knee at random (one knee per person).

Participants underwent bilateral posteroanterior fixed-flexion weight-bearing x-ray at baseline and annually through year 4, and then every two years until year 10; x-rays were centrally read for KL grade. 3T MRI was acquired at clinic visits up to year 8; longitudinal structural abnormalities in knees identified as cases and/or in the subcohort were graded using the MRI Osteoarthritis Knee Score (MOAKS).

We fit Cox models for time to iRKOA, with subcohort controls weighted inversely proportional to the sampling fraction; longitudinal structural features were included as time-varying predictors, lagged from the visit prior to each x-ray to establish temporality. We fit feature-specific models for bone marrow lesions (BML), cartilage damage, and meniscal damage with maximum scores in each compartment (i.e., medial tibiofemoral [TF], lateral TF, patellofemoral [PF]), as well as an inflammation model for whole-knee effusion-synovitis (ES) and Hoffa-synovitis (HS). We also fit a full model with all features.

Results: Time to iRKOA is shown in Figure 2. The subcohort reflected the parent cohort, with a mean age of 60 years (SD 9), 55% female, 84% white and 14% African American, and predominately overweight (40%) or obese (32%).

In feature-specific models, all structural abnormalities were associated with iRKOA, and in nearly every compartment. The magnitude of association for specific abnormalities attenuated in the full model that included all features, though medium/large ES and PF cartilage damage of >10% surface area with >10% full-thickness or >75% surface area was associated with at least a two-fold increase in risk of iRKOA (based on lower bounds of the 95%CIs). Small ES, large medial TF BMLs, and PFJ cartilage damage of 10-75% surface area with any full-thickness, and lateral meniscus maceration were estimated to increase risk by at least 50% (Table 1).

Conclusion: While all structural abnormalities were associated with iRKOA in at least one compartment, our findings suggest that ES, PF cartilage damage, large medial TF BMLs, and lateral meniscus maceration are particularly indicative of increased risk of iRKOA. Varied structural abnormalities associated with knee OA development suggests heterogenous disease pathology that may require custom multifaceted treatment approaches.

Figure 1

Figure 2

Table 1


Disclosure: C. Kwoh, Abbvie, 2, Merck KGaA, 2, 5, Fidia, 5, Thusane Astellas, 5, Regulus, 5, Taiwan Liposome, 5, Regeneron, 5, EMD Serono, 5, Express Scripts, 5, Kolon Tissue Gene, 5, Pfizer, 2, UCB, 2, Novartis, 2, Eli Lilly, 2, GSK, 2; A. Guermazi, AstraZeneca, 1, Pfizer, 1, MerckSerono, 1, Galapagos, 1, Roche, 1, TissueGene, 1, Boston Imaging Core Lab, 1; E. Ashbeck, EMD Serono, 5; C. Hu, None; E. Bedrick, None; L. Sharma, None; C. Eaton, None; M. Hochberg, Bone Therapeutics, 5, Bristol Myers Squibb, 5, Eli Lilly, 5, EMD Serono, 5, Gilead, 5, GlaxoSmithKline, 5, IBSA Institut Biochimique SA, 5, Novartis Pharma AG, 5, Noven Pharmaceuticals Inc., 5, Pfizer Inc., 5, Regenosine, 5, Samumed LLC, 5, Theralogix LLC, 5, Vizuri Health Sciences, 5, ACI Clinical, 5, Covance Inc., 5, Galapagos, 5, ICON plc, 5, IQVIA, 5, Elsevier, 7, Wolters Kluwer, 7, BriOri Biotech, 1, Theralogix LLC., 1, Rheumcon, Inc., 6; R. Jackson, None; T. McAlindon, Pfizer, 1, Sanofi Aventis US, 1, Kolon Tissuegene, 1, Samumed, 1, Seikagaku, 1, Kiniksa Pharmaceuticals, 1, Anika Therapeutics, 1; M. Nevitt, None; J. Cauley, None; F. Roemer, Boston Imaging Core Lab (BICL), LLC, 1, Calibr - California Institute for Biomedical Research, 1.

To cite this abstract in AMA style:

Kwoh C, Guermazi A, Ashbeck E, Hu C, Bedrick E, Sharma L, Eaton C, Hochberg M, Jackson R, McAlindon T, Nevitt M, Cauley J, Roemer F. Longitudinally Assessed Structural Abnormalities on MRI and Relative Contributions to Risk of Incident Radiographic Knee Osteoarthritis over 10 Years of Follow-up [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 10). https://acrabstracts.org/abstract/longitudinally-assessed-structural-abnormalities-on-mri-and-relative-contributions-to-risk-of-incident-radiographic-knee-osteoarthritis-over-10-years-of-follow-up/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2020

ACR Meeting Abstracts - https://acrabstracts.org/abstract/longitudinally-assessed-structural-abnormalities-on-mri-and-relative-contributions-to-risk-of-incident-radiographic-knee-osteoarthritis-over-10-years-of-follow-up/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology